C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
C4 Therapeutics, Inc.NASDAQ: CCCC
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$64K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$671K. Over 3 fiscal years it compounded at -52.0% a year.
Context
- Capital expenditures amounted to 1.7% of revenue in FY2025, up 1.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$64K or moves back toward the trailing-twelve-month quarterly average of -$167.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (607K) USD
- Year-over-year change
- -237.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (607K) | -237.2% |
| FY2024 | 2024-12-31 | (180K) | +89.5% |
| FY2023 | 2023-12-31 | (1.71M) | +68.9% |
| FY2022 | 2022-12-31 | (5.5M) | -330.4% |
| FY2021 | 2021-12-31 | (1.28M) | — |
Capital Expenditures vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +272.8% is the 2nd highest of 9, against a peer median of -55.9%.
- Capital expenditures amounts to 1.9% of revenue for CCCC, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.49M USD | +602.4% | -9.8% | 179.1% |
| LTM Mar 2026 | $3.39M USD | -23.5% | -18.7% | 4.3% | |
| LTM Mar 2026 | $671K USD | +272.8% | -52.0% | 1.9% | |
| LTM Mar 2026 | $523K USD | -54.8% | -68.0% | 1.8% | |
| LTM Mar 2026 | $506K USD | -70.7% | -37.4% | 17.1% | |
| LTM Mar 2026 | CHF 333.55K CHF | -67.9% | -20.4% | — | |
| LTM Mar 2026 | $139K USD | -75.6% | -58.7% | — | |
| LTM Mar 2026 | $115K USD | -56.9% | -82.8% | 0.3% | |
| LTM Mar 2026 | $68.98K USD | +76.9% | +3.5% | 3.9% | |
| Peer median (excluding CCCC) | — | -55.9% | -28.9% | 4.1% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Depreciation & Amortization | 1.49M | 1.68M | 1.88M | 1.82M | 1.96M |
| Deferred Income Tax | 1.88M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 21.51M | 30.02M | 27.24M | 29.66M | 19.1M |
| Change in Working Capital | (30.09M) | (16.78M) | (6.94M) | 7.65M | (29.28M) |
| Accounts Receivables | (1.23M) | 4.24M | (10.33M) | 8.7M | 701K |
| Inventory | (2.63M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.18M) | (3.33M) | 273K | (119K) | (468K) |
| Other Working Capital | (25.05M) | (17.69M) | 3.12M | (930K) | (29.52M) |
| Other Non-Cash Items | 2.13M | 7.32M | 3.48M | 1.03M | 14.52M |
| Operating Cash Flow | (86.97M) | (105.94M) | (106.84M) | (65.16M) | (98.69M) |
| Capital Expenditures | (1.28M) | (5.5M) | (1.71M) | (180K) | (607K) |
| Acquisitions (Net) | 188.06M | (63.92M) | 0 | 0 | 0 |
| Purchases of Investments | (537.74M) | (219.53M) | (129.9M) | (284.32M) | (227.07M) |
| Sales of Investments | 349.68M | 283.45M | 289.96M | 233.23M | 219.08M |
| Other Investing Activities | (188.06M) | 63.92M | 0 | 0 | 0 |
| Investing Cash Flow | (189.34M) | 58.42M | 158.35M | (51.27M) | (8.6M) |
| Debt Repayment | 0 | 0 | (12.5M) | 0 | 0 |
| Common Stock Issued | 169.47M | 777K | 57.67M | 44.37M | 126.32M |
| Common Stock Repurchased | 0 | 0 | (110K) | (194K) | (193K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 370K | 426K | 1.16M | 274K |
| Financing Cash Flow | 171.4M | 1.15M | 45.49M | 45.34M | 126.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (104.9M) | (46.37M) | 97M | (71.09M) | 19.1M |
| Free Cash Flow | (88.24M) | (111.44M) | (108.55M) | (65.34M) | (99.3M) |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.